Biosimilar Interchangeability Does Not Create Substitution Under House Bills

While biosimilars legislation is seen as a means of lowering health care costs, interchangeability provisions in House bills creating a biosimilars approval pathway would not be enough to allow automatic substitution at the pharmacy level - the route to the highest savings